SG10201910521YA - Pharmaceutical Compositions Comprising (3-(1-(1H-Imidazol-4-yl)Ethyl)-2-Methylphenyl) Methanol - Google Patents

Pharmaceutical Compositions Comprising (3-(1-(1H-Imidazol-4-yl)Ethyl)-2-Methylphenyl) Methanol

Info

Publication number: SG10201910521YA
Authority: SG; Singapore
Prior art keywords: imidazol; methylphenyl; methanol; ethyl; pharmaceutical compositions
Prior art date: 2010-11-16

Application number

SG10201910521YA

Inventor

Mohammed I Dibas

John E Donello

Daniel W Gil

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-16

Filing date

2011-11-10

Publication date

2020-01-30

2011-11-10 Application filed by Allergan Inc filed Critical Allergan Inc

2020-01-30 Publication of SG10201910521YA publication Critical patent/SG10201910521YA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

SG10201910521YA 2010-11-16 2011-11-10 Pharmaceutical Compositions Comprising (3-(1-(1H-Imidazol-4-yl)Ethyl)-2-Methylphenyl) Methanol SG10201910521YA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41418010P	2010-11-16	2010-11-16

Publications (1)

Publication Number	Publication Date
SG10201910521YA true SG10201910521YA (en)	2020-01-30

Family

ID=44999965

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG2013038153A SG190322A1 (en)	2010-11-16	2011-11-10	Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2- methylphenyl)methanol
SG10201509423XA SG10201509423XA (en)	2010-11-16	2011-11-10	Pharmaceutical Compositions Comprising (3-(1-(1H-Imidazol-4-yl)Ethyl)-2-Methylphenyl) Methanol
SG10201910521YA SG10201910521YA (en)	2010-11-16	2011-11-10	Pharmaceutical Compositions Comprising (3-(1-(1H-Imidazol-4-yl)Ethyl)-2-Methylphenyl) Methanol

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SG2013038153A SG190322A1 (en)	2010-11-16	2011-11-10	Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2- methylphenyl)methanol
SG10201509423XA SG10201509423XA (en)	2010-11-16	2011-11-10	Pharmaceutical Compositions Comprising (3-(1-(1H-Imidazol-4-yl)Ethyl)-2-Methylphenyl) Methanol

Country Status (17)

Country	Link
US (6)	US20120149747A1 (en)
EP (3)	EP3795154A1 (en)
JP (1)	JP2013542991A (en)
KR (8)	KR20220158876A (en)
CN (1)	CN103298467A (en)
AR (1)	AR083893A1 (en)
AU (1)	AU2011329209B8 (en)
BR (1)	BR112013012112A2 (en)
CA (2)	CA2818144C (en)
DK (1)	DK3093017T3 (en)
ES (1)	ES2865118T3 (en)
IL (1)	IL226384A (en)
MX (2)	MX385460B (en)
RU (1)	RU2013124526A (en)
SG (3)	SG190322A1 (en)
TW (1)	TW201304774A (en)
WO (1)	WO2012067941A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2010213580A1 (en)	2009-02-13	2011-09-08	Allergan, Inc.	Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
AU2012340806B2 (en)	2011-11-21	2017-10-19	Allergan, Inc.	Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
WO2025179071A1 (en) *	2024-02-20	2025-08-28	Bausch + Lomb Ireland Limited	Sustained-release drug delivery compositions for treating ocular diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9813381A (en) *	1997-12-04	2000-10-03	Allergan Sales Inc	"substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b / 2c adrenergic receptors"
US20020198210A1 (en)	2001-05-03	2002-12-26	Allergan Sales Inc.	Alpha-2-adrenergic agonist/fatty acid compositions
US7642258B2 (en) *	2002-04-19	2010-01-05	Allergan, Inc.	Combination of brimonidine and timolol for topical ophthalmic use
US7091232B2 (en) *	2002-05-21	2006-08-15	Allergan, Inc.	4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7439241B2 (en) *	2003-05-27	2008-10-21	Galderma Laboratories, Inc.	Compounds, formulations, and methods for treating or preventing rosacea
CN1878569A (en) *	2003-09-12	2006-12-13	阿勒根公司	Methods and compositions for treating pain and other alpha2-adrenergic mediated disorders
US20050059744A1 (en)	2003-09-12	2005-03-17	Allergan, Inc.	Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050244463A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Sustained release intraocular implants and methods for treating ocular vasculopathies
PL1761266T3 (en) *	2004-05-25	2013-09-30	Galderma Pharma Sa	Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
GB0611241D0 (en) *	2006-06-07	2006-07-19	Daniolabs Ltd	The treatment of increased sebum production
GB0715790D0 (en)	2007-08-13	2007-09-26	Summit Corp Plc	Drug combination for the treatment of sialorrhoea
EP2320911B1 (en) *	2008-08-01	2014-10-08	Eye Therapies LLC	Vasoconstriction compositions and methods of use
AU2010213580A1 (en)	2009-02-13	2011-09-08	Allergan, Inc.	Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

2011
- 2011-11-10 KR KR1020227040513A patent/KR20220158876A/en not_active Ceased
- 2011-11-10 CA CA2818144A patent/CA2818144C/en active Active
- 2011-11-10 KR KR1020137015295A patent/KR101891846B1/en active Active
- 2011-11-10 SG SG2013038153A patent/SG190322A1/en unknown
- 2011-11-10 BR BR112013012112A patent/BR112013012112A2/en not_active IP Right Cessation
- 2011-11-10 JP JP2013539910A patent/JP2013542991A/en active Pending
- 2011-11-10 RU RU2013124526/15A patent/RU2013124526A/en not_active Application Discontinuation
- 2011-11-10 EP EP20200021.2A patent/EP3795154A1/en active Pending
- 2011-11-10 MX MX2016009578A patent/MX385460B/en unknown
- 2011-11-10 KR KR1020207019691A patent/KR20200085936A/en not_active Ceased
- 2011-11-10 KR KR1020197034456A patent/KR102090441B1/en active Active
- 2011-11-10 AU AU2011329209A patent/AU2011329209B8/en active Active
- 2011-11-10 KR KR1020217019125A patent/KR20210080591A/en not_active Ceased
- 2011-11-10 MX MX2013005439A patent/MX340859B/en active IP Right Grant
- 2011-11-10 SG SG10201509423XA patent/SG10201509423XA/en unknown
- 2011-11-10 EP EP11785262.4A patent/EP2640382B1/en active Active
- 2011-11-10 CA CA3067290A patent/CA3067290A1/en active Pending
- 2011-11-10 EP EP16176846.0A patent/EP3093017B1/en active Active
- 2011-11-10 DK DK16176846.0T patent/DK3093017T3/en active
- 2011-11-10 SG SG10201910521YA patent/SG10201910521YA/en unknown
- 2011-11-10 WO PCT/US2011/060236 patent/WO2012067941A1/en not_active Ceased
- 2011-11-10 CN CN2011800647548A patent/CN103298467A/en active Pending
- 2011-11-10 ES ES16176846T patent/ES2865118T3/en active Active
- 2011-11-10 KR KR1020187023705A patent/KR102050187B1/en active Active
- 2011-11-10 KR KR1020207007148A patent/KR102134117B1/en active Active
- 2011-11-10 KR KR1020247024450A patent/KR20240118184A/en not_active Ceased
- 2011-11-15 US US13/297,212 patent/US20120149747A1/en not_active Abandoned
- 2011-11-16 TW TW100141941A patent/TW201304774A/en unknown
- 2011-11-16 AR ARP110104278A patent/AR083893A1/en not_active Application Discontinuation
2013
- 2013-05-16 IL IL226384A patent/IL226384A/en active IP Right Grant
2015
- 2015-11-19 US US14/945,874 patent/US20160067222A1/en not_active Abandoned
2017
- 2017-01-05 US US15/399,460 patent/US20170172983A1/en not_active Abandoned
2019
- 2019-08-07 US US16/534,712 patent/US20200206193A1/en not_active Abandoned
2021
- 2021-02-18 US US17/179,271 patent/US20220008393A1/en not_active Abandoned
2024
- 2024-08-23 US US18/813,414 patent/US20250228823A1/en active Pending

Also Published As

Publication number	Publication date
EP3093017B1 (en)	2021-01-06
US20250228823A1 (en)	2025-07-17
KR102134117B1 (en)	2020-07-15
CA3067290A1 (en)	2012-05-24
AR083893A1 (en)	2013-03-27
KR20200085936A (en)	2020-07-15
AU2011329209B8 (en)	2017-03-09
EP2640382A1 (en)	2013-09-25
KR20190133071A (en)	2019-11-29
IL226384A0 (en)	2013-07-31
TW201304774A (en)	2013-02-01
SG190322A1 (en)	2013-06-28
KR101891846B1 (en)	2018-08-24
KR102050187B1 (en)	2019-11-28
MX2013005439A (en)	2013-08-27
US20120149747A1 (en)	2012-06-14
BR112013012112A2 (en)	2016-09-27
KR20180096812A (en)	2018-08-29
US20160067222A1 (en)	2016-03-10
KR20140008316A (en)	2014-01-21
KR20240118184A (en)	2024-08-02
RU2013124526A (en)	2014-12-27
AU2011329209A1 (en)	2013-06-13
AU2011329209B2 (en)	2017-02-23
ES2865118T3 (en)	2021-10-15
US20220008393A1 (en)	2022-01-13
CA2818144A1 (en)	2012-05-24
EP3093017A1 (en)	2016-11-16
KR20200030626A (en)	2020-03-20
KR20220158876A (en)	2022-12-01
US20170172983A1 (en)	2017-06-22
WO2012067941A1 (en)	2012-05-24
EP3795154A1 (en)	2021-03-24
JP2013542991A (en)	2013-11-28
CN103298467A (en)	2013-09-11
CA2818144C (en)	2020-09-22
KR20210080591A (en)	2021-06-30
US20200206193A1 (en)	2020-07-02
IL226384A (en)	2017-06-29
KR102090441B1 (en)	2020-03-18
MX340859B (en)	2016-07-28
SG10201509423XA (en)	2015-12-30
EP2640382B1 (en)	2016-10-19
DK3093017T3 (en)	2021-04-06
MX385460B (en)	2025-03-18
AU2011329209A8 (en)	2017-03-09

Publication	Publication Date	Title
EP2416758B8 (en)	2017-10-18	Antimycotic pharmaceutical composition
PT2323623T (en)	2016-11-04	Pharmaceutical compositions
SI3050564T1 (en)	2020-02-28	Ester pro-drugs of (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl) methanol
IL211143A0 (en)	2011-04-28	Therapeutic compositions containing macitentan
IL221212A0 (en)	2012-10-31	Ethanol compositions
EP2542082B8 (en)	2020-06-17	PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-perillyl alcohol
DK3566703T3 (en)	2021-07-05	PHARMACEUTICAL COMPOSITIONS INCLUDING (3- (1- (1H-IMIDAZOL-4-YL) ETHYL) -2-METHYLPHENYL) METHANOL
EP2394996B8 (en)	2016-10-19	Phenylimidazole compounds
SG10201710156RA (en)	2018-01-30	4-methylpyrazole formulations
IL226384A0 (en)	2013-07-31	Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
GB0806745D0 (en)	2008-05-14	Novel imidazole derivatives
ZA201100163B (en)	2011-09-28	Unit dosage of apadenoson
HK1163558A (en)	2012-09-14	Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl) methanol
GB0904315D0 (en)	2009-04-22	Novel imidazole derivatives
AU2013257527A1 (en)	2013-12-05	Unit dosage of apadenoson
HK1152929A (en)	2012-03-16	Bis-aryl compounds for use as medicaments
TWM388532U (en)	2010-09-11	Wall sheet structure for architecture
HK1171692A (en)	2013-04-05	Sustained-release formulation
AU2008906012A0 (en)	2008-12-04	Therapeutic compositions
GB0806283D0 (en)	2008-05-14	Pharmaceutical compositions
GB0802024D0 (en)	2008-03-12	Pharmaceutical compositions
GB0806156D0 (en)	2008-05-14	Pharmaceutical compositions
EP2308842A4 (en)	2012-03-14	Pharmaceutical compositions
HK1187534A (en)	2014-04-11	Pharmaceutical composition comprising deferasirox
HK1161766A (en)	2012-08-03	Using gpu for network packetization